ArticleFrontiers in immunology2025
Identification of prognosis and therapy related intratumoral microbiome and immune signatures in gastric cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immune-inflammatory-fibrinogen score as a novel prognostic biomarker in patients with gastric cancer undergoing radical gastrectomy: a multicenter study.World journal of surgical oncology · 2026Trial
- Identification of a novel ion channel-related gene signature to predict prognosis and immune response of gastric cancer.Translational cancer research · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impact of the intratumoral microbiome (ITM) on the treatment and prognosis of gastric cancer (GC) remains controversial. Our study analyzed the differential ITM in GC tissues and identified nine bacterial genera significantly associated with overall survival (OS), with seven as risk factors and two as protective factors. Three distinct clusters with varying survival outcomes were defined, demonstrating correlations with pathological stage and immune features. An immune-related gene-based RiskScore model incorporating genes such as Apolipoprotein D (APOD), Stanniocalcin 1 (STC1), Coagulation Factor II Thrombin Receptor (F2R), Angiotensinogen (AGT), Fatty Acid Binding Protein 4 (FABP4), Inhibin Subunit Beta A (INHBA), Caspase Recruitment Domain Family Member 11 (CARD11), and Dickkopf WNT Signaling Pathway Inhibitor 1 (DKK1) was established and validated in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. When combined with clinical factors, this RiskScore model formed a Nomogram model achieving Areas Under the Curve (AUCs) of 0.72, 0.76, and 0.79 for 1, 3, and 5-year OS predictions, respectively. This model exhibited robust predictive accuracy over time and correlated with mutation frequency, drug sensitivity, and immunotherapy response. Furthermore, single-cell analysis revealed that tumor-associated fibroblasts may play a pivotal role in immune-microbial interactions. The results were confirmed using quantitative real-time polymerase chain reaction (qPCR) and immunohistochemistry (IHC). In conclusion, the prognostic model incorporating ITM and immune-related genes aids in risk stratification and provides valuable insights and targets for GC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.